For example, GCKR variants are known to influence glucose and lipid metabolism, with elevated glucokinase activity promoting de novo hepatic lipogenesis and inhibiting fatty acid oxidation, mechanisms implicated in NAFLD development [31, 32]. Here, GCKR is linked to metabolic dysfunction-associated steatotic liver disease.